<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04420260</url>
  </required_header>
  <id_info>
    <org_study_id>UNIGEM PT-IC-02</org_study_id>
    <nct_id>NCT04420260</nct_id>
  </id_info>
  <brief_title>Primary Prevention of Infection by COVID-19 in Workers</brief_title>
  <acronym>PI-Covid-19</acronym>
  <official_title>Scheme of Primary Prevention of Infection by COVID-19, in Workers: Phase II Controlled Clinical Trial, to be Carried Out in Medellín-Antioquia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unidad de Investigación Genética Molecular</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de Antioquia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unidad de Investigación Genética Molecular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: The SARS Co-2 contagious rate is high (Ro: 2.0-3.0). The infection is&#xD;
      aggressive with high pathogenicity. Global confinement impacts all social and economic fields&#xD;
      of human activity. Clinical behavior exceeds the capabilities of public health care. With the&#xD;
      initial information on the pandemic, it is estimated that 20% of health personnel in direct&#xD;
      contact with patients can acquire the disease, despite preventive self-care. The molecular&#xD;
      relationship of COVID-19 with the subject's ACE2 protein encourages the virus to enter the&#xD;
      host cell, and initiates replication and the immune response, causing an imbalance generating&#xD;
      an immunological storm of cytokines, with serious damage to the host.&#xD;
&#xD;
      Objective: It is proposed to supply a combined scheme of two compounds by oropharyngeal spray&#xD;
      that captures the virus before entering the target cell and orally administer&#xD;
      immunomodulatory compounds that regulate the inflammatory response released by the virus, in&#xD;
      order to improve the antiviral response.&#xD;
&#xD;
      Methodology: A controlled, parallel design, triple-blind, phase II clinical trial will be&#xD;
      conducted with two study groups to compare the active compounds (oropharyngeal spray and&#xD;
      emulsion) with placebo.&#xD;
&#xD;
      Discussion: With the application of the combined scheme of two compounds, a 75% reduction in&#xD;
      infection is expected for workers in direct contact with COVID patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESEARCH QUESTION: Can the oropharyngeal spray of a viral blocking compound in conjunction&#xD;
      with the provision of an immunostimulant emulsion, reduce the infection proportion by 2/3&#xD;
&#xD;
      ACTIVE PRINCIPLE Intervention 1. BlockACE2® spray, antimicrobial and antiviral liquid&#xD;
      solution for mouth spray, composed of 3 natural bioactive substances proven to be used in&#xD;
      humans, which present molecular structures homologous to the native receptor of the virus. It&#xD;
      contains binding peptides that resemble the ACE2 receptor, which bind to viral fractions, and&#xD;
      acts as soluble scavengers of the virus at the entrance gate, upper respiratory tract, or&#xD;
      oropharyngeal region, preventing its entry into the target cell and decreasing the amount of&#xD;
      virus that enters the body; consequently, they reduce their ability to generate damage.&#xD;
&#xD;
      BlockACE2® Defense, food for oral administration in the form of an emulsion with 8 bioactive&#xD;
      components that have shown modulation of the inflammatory response. Contains natural oils,&#xD;
      Vitamin B6, Vitamin C, Vitamin E, Vitamin D3 100 SD / S, and minerals; key micronutrients&#xD;
      that are not normally obtained through a traditional diet. These nutrients are&#xD;
      immunostimulants with proven capacity to enhance the cellular response against viruses,&#xD;
      anti-inflammatory, antioxidant, and chemoprotective activity, stimulating the production of&#xD;
      interferon I; and as a whole, they prevent the generation of an excessive immune activation&#xD;
      process, known as an &quot;immune storm&quot; mediated by pro-inflammatory cytokines.&#xD;
&#xD;
      Intervention 2, Placebo:&#xD;
&#xD;
      Preparations without active components in the pharmaceutical form of the above (Intervention&#xD;
      1 and Intervention 2). They will be presented with the same physical characteristics such as&#xD;
      size, shape, color, taste, smell, consistency, printed signs, weight, surface finish,&#xD;
      internal and external; in order to guarantee the principle of masking.&#xD;
&#xD;
      RESEARCH HYPOTHESIS:&#xD;
&#xD;
      In a population with community risk of COVID-19 infection, the combined use of the study&#xD;
      interventions (the oral antimicrobial solution in Spray BlockACE2® and the food in BlockACE2®&#xD;
      emulsion, compared to the use of Placebo, reduces the risk of COVID-19 infection expressed in&#xD;
      a negative PCR result in those who seroconvert to IgM, and in those who seroconvert, the&#xD;
      higher proportion will be in the mild-moderate clinical form.&#xD;
&#xD;
      PRIMARY OBJECTIVE To establish the efficacy of the combined use of BlockACE2® oropharyngeal&#xD;
      spray, and BlockACE2® emulsion, in comparison with placebo on the reduction of the risk of&#xD;
      infection by COVID-19, expressed in the negative result of immunoglobulins for COVID-19 (30&#xD;
      days from admission to the project).&#xD;
&#xD;
      Establish the safety of the products under study by evaluating the expected and unexpected&#xD;
      adverse events that are recorded during the use phase of the intervention scheme (30 days&#xD;
      from project entry).&#xD;
&#xD;
      SECONDARY OBJECTIVE To establish the efficacy of the combined use of BlockACE2® spray, a&#xD;
      soluble virus scavenger compound plus ingestion of BlockACE2® emulsion, a compound that&#xD;
      improves the defenses of the immune system, compared to placebo, on reducing the risk of&#xD;
      infection by COVID-19 expressed in the clinical response of the disease that is defined in&#xD;
      three variables, mild to moderate: onset of fever, myalgia, and cough without dyspnea;&#xD;
      severe: fever, myalgia, cough and dyspnea requiring hospital care; and critical: all the&#xD;
      above plus ventilatory assistance in ICU.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES Explore the efficacy of the combined use of BlockACE2® spray, a&#xD;
      soluble virus scavenger compound, plus the intake of BlockACE2®, an emulsion food with key&#xD;
      micronutrients that stimulate the antiviral cellular immune response on reducing the risk of&#xD;
      COVID-19 infection expressed in the negative result of IgG, IgM; and the reduction of the&#xD;
      risk of symptoms such as fever, cough, dyspnea, myalgia, or ventilatory assistance in the ICU&#xD;
      after 15 days of finishing the scheme.&#xD;
&#xD;
      FIELD OF STUDY: Workers of every department of Conconcreto Company in the city of Medellín&#xD;
      and Girardota&#xD;
&#xD;
      INTERVENTIONS:&#xD;
&#xD;
      Intervention 1 BLOCKACE2: Two oropharyngeal sprays of the compound, every 4 hours, during the&#xD;
      day. For the BlockACE2 emulsion will be used 20 ml during the first 5 days and after it only&#xD;
      10ml every day for 30 days. Dosing of the substances in intervention 1 follows the described&#xD;
      pharmacological characteristics, that guarantee its permanence in the oral mucosa to protect&#xD;
      the entry pathway of the virus into the organism (Oropharynx). The dosage of the oral&#xD;
      compounds was defined according to recommendations of the WHO for the modulation of the&#xD;
      immune response (Emulsion).&#xD;
&#xD;
      Intervention 2 PLACEBO: spray and emulsion with similar color, smell, and texture but without&#xD;
      the natural active compounds.&#xD;
&#xD;
      In the randomization visit V1, each participant will be assigned a treatment scheme, composed&#xD;
      of intervention 1 and intervention 2, in sufficient quantity for the duration of the study.&#xD;
      The pharmaceutical service will dispense the code of the scheme, following a sequential&#xD;
      order, indicated in an allocation listing of the schemes on site. Each treatment scheme is&#xD;
      labeled with a unique code that identifies it, and it contains One (1) device for&#xD;
      oropharyngeal spray, with a capacity for 200 applications. One (1) bottle with 360 ml (oral).&#xD;
      In the subsequent visits, the adherence to the dispensed schemes will be verified. The&#xD;
      frequency of use will be checked, and dosing omissions will be registered by frequency (1&#xD;
      dose, once a week, more than once a week).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Actual">July 5, 2021</completion_date>
  <primary_completion_date type="Actual">June 23, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Combination of an oropharyngeal spray and an oral immunostimulant agent for the prevention of COVID-19 infection in workers in Medellín-Antioquia. The randomized clinical trial, parallel design, triple-blind, phase II.&#xD;
Combination of an oropharyngeal spray and an oral immunostimulant agent for the prevention of COVID-19 infection in workers in Medellín-Antioquia. The randomized clinical trial, parallel design, triple-blind, phase II.&#xD;
A two-arm is stipulated, in the following manner:&#xD;
Group A: Active principle spray + Active principle emulsion. Group B: Placebo spray + Placebo emulsion.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Once the participant has given its informed consent, and the research team has verified the fulfillment of the inclusion criteria, the prospect receives a text message, to be directed to the pharmaceutical service. The numbered scheme will be dispensed with the code of the intervention, following the order from the allocation listing, provided by the CTCC. The head of the pharmaceutical service will register the date and time of the first dose. He will provide indications for the use, handling, and conservation of the products. Warning signs and symptoms and instructions for communication with the research team to address any concerns the subject may have will be reviewed. He will remind the subject to avoid its damage or loss. He will give the participant instructions to return the container and surpluses of the products at the end of the trial (day 30), he will point out that they are for personal use only and that they cannot be shared.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion of IgM for COVID-19.</measure>
    <time_frame>1 month</time_frame>
    <description>Seroconversion of IgM for COVID-19. Result of positive IgM antibodies: A previously scheduled closure visit will be conducted, the trial product will be interrupted if a case is classified as severe-critical, and clinical follow up will be continued as planned. As protocols by the Health Ministry dictate, cases will be confirmed with a PCR-RT test, for the diagnosis of COVID-19. The result of the test will be requested to document the outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion of IgG for COVID-19.</measure>
    <time_frame>through study completion, 45 days</time_frame>
    <description>seroconversion of IgG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Treatment oropharyngeal spray + immunostimulant emulsion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active principle oropharyngeal spray + Active principle immunostimulant taken PO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oropharyngeal spray + Placebo emulsion was taken PO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Group A: oropharygeal spray and immunostimulant emulsion</intervention_name>
    <description>Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of 3 natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.&#xD;
Intervention 2. Preparation in an emulsion functional food presentation for oral administration, that contains the 8 bioactive compounds that have demonstrated antiviral activity and modulation of the inflammatory response recognized at the moment in the immune activation against the virus.</description>
    <arm_group_label>Treatment oropharyngeal spray + immunostimulant emulsion</arm_group_label>
    <other_name>BLOCKACE2 (oropharyngeal spray) + BLOCKACE2 Emulsion (Active principle immunostimulant )</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Group D:Placebo oropharyngeal spray + Placebo taken PO</intervention_name>
    <description>Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of Placebo substances of routine use in humans.&#xD;
Intervention 2. Preparation in an emulsion presentation for oral administration that contains the Placebo compounds</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo+ Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 and 60 years.&#xD;
&#xD;
          2. Health care worker in the front line of care of suspected or confirmed cases of&#xD;
             COVID-19.&#xD;
&#xD;
          3. Negative IgM antibodies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Being a participant in another trial with another drug.&#xD;
&#xD;
          2. Temperature above 38ºC.&#xD;
&#xD;
          3. Having cohabited in the past 15 days with a person diagnosed with CoV-19.&#xD;
&#xD;
          4. Pregnancy.&#xD;
&#xD;
          5. Active o past smoker.&#xD;
&#xD;
          6. Known hypersensitivity to drugs or food.&#xD;
&#xD;
          7. History of respiratory disease.&#xD;
&#xD;
          8. Underlying diseases (Hypertension, cancer, diabetes, cardiovascular disease,&#xD;
             leukopenia).&#xD;
&#xD;
          9. Signs or symptoms of CoV-19 infection: cough, dyspnea, myalgias.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatriz H Aristizabal, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidad de Investigación Genética Molecular</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beatriz Aristizabal</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050021</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus. Front Microbiol. 2019 Aug 2;10:1781. doi: 10.3389/fmicb.2019.01781. eCollection 2019.</citation>
    <PMID>31428074</PMID>
  </reference>
  <reference>
    <citation>Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses. 2019 Jan 14;11(1):59. doi: 10.3390/v11010059.</citation>
    <PMID>30646565</PMID>
  </reference>
  <reference>
    <citation>Thomas SJ, L'Azou M, Barrett AD, Jackson NA. Fast-Track Zika Vaccine Development - Is It Possible? N Engl J Med. 2016 Sep 29;375(13):1212-6. doi: 10.1056/NEJMp1609300. No abstract available.</citation>
    <PMID>27682032</PMID>
  </reference>
  <reference>
    <citation>Koch S, Pong W, Editors. The count of companies developing vaccines for coronavirus rises 2020 [Internet]. Redwood: BioCentury; 2020 [cited 2020 Feb 16]. Available from: https://www.biocentury.com/article/304412</citation>
  </reference>
  <reference>
    <citation>Ma-Lauer Y, Zheng Y, Malesevic M, von Brunn B, Fischer G, von Brunn A. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Res. 2020 Jan;173:104620. doi: 10.1016/j.antiviral.2019.104620. Epub 2019 Oct 18.</citation>
    <PMID>31634494</PMID>
  </reference>
  <reference>
    <citation>Shakya A, Bhat HR, Ghosh SK. Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent. Curr Drug Discov Technol. 2018;15(3):201-213. doi: 10.2174/1570163814666170727130003.</citation>
    <PMID>28748751</PMID>
  </reference>
  <reference>
    <citation>Pervushin K, Tan E, Parthasarathy K, Lin X, Jiang FL, Yu D, Vararattanavech A, Soong TW, Liu DX, Torres J. Structure and inhibition of the SARS coronavirus envelope protein ion channel. PLoS Pathog. 2009 Jul;5(7):e1000511. doi: 10.1371/journal.ppat.1000511. Epub 2009 Jul 10.</citation>
    <PMID>19593379</PMID>
  </reference>
  <reference>
    <citation>Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A, Brock G, Montefiori DC, Vojdani F, McCormick AA, O'Keefe BR, Palmer KE. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother. 2014;58(1):120-7. doi: 10.1128/AAC.01407-13. Epub 2013 Oct 21.</citation>
    <PMID>24145548</PMID>
  </reference>
  <reference>
    <citation>Pruijssers AJ, Denison MR. Nucleoside analogues for the treatment of coronavirus infections. Curr Opin Virol. 2019 Apr;35:57-62. doi: 10.1016/j.coviro.2019.04.002. Epub 2019 May 21.</citation>
    <PMID>31125806</PMID>
  </reference>
  <reference>
    <citation>Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019 Apr;14(4):397-412. doi: 10.1080/17460441.2019.1581171. Epub 2019 Mar 8.</citation>
    <PMID>30849247</PMID>
  </reference>
  <reference>
    <citation>Mielech AM, Kilianski A, Baez-Santos YM, Mesecar AD, Baker SC. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology. 2014 Feb;450-451:64-70. doi: 10.1016/j.virol.2013.11.040. Epub 2013 Dec 22.</citation>
    <PMID>24503068</PMID>
  </reference>
  <reference>
    <citation>Momattin H, Al-Ali AY, Al-Tawfiq JA. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Travel Med Infect Dis. 2019 Jul-Aug;30:9-18. doi: 10.1016/j.tmaid.2019.06.012. Epub 2019 Jun 25.</citation>
    <PMID>31252170</PMID>
  </reference>
  <reference>
    <citation>Sutton TC, Subbarao K. Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus. Virology. 2015 May;479-480:247-58. doi: 10.1016/j.virol.2015.02.030. Epub 2015 Mar 16.</citation>
    <PMID>25791336</PMID>
  </reference>
  <reference>
    <citation>Mubarak A, Alturaiki W, Hemida MG. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. J Immunol Res. 2019 Apr 7;2019:6491738. doi: 10.1155/2019/6491738. eCollection 2019.</citation>
    <PMID>31089478</PMID>
  </reference>
  <reference>
    <citation>Wiley JA, Richert LE, Swain SD, Harmsen A, Barnard DL, Randall TD, Jutila M, Douglas T, Broomell C, Young M, Harmsen A. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS One. 2009 Sep 23;4(9):e7142. doi: 10.1371/journal.pone.0007142.</citation>
    <PMID>19774076</PMID>
  </reference>
  <reference>
    <citation>Wohlford-Lenane CL, Meyerholz DK, Perlman S, Zhou H, Tran D, Selsted ME, McCray PB Jr. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J Virol. 2009 Nov;83(21):11385-90. doi: 10.1128/JVI.01363-09. Epub 2009 Aug 26.</citation>
    <PMID>19710146</PMID>
  </reference>
  <reference>
    <citation>Adedeji AO, Sarafianos SG. Antiviral drugs specific for coronaviruses in preclinical development. Curr Opin Virol. 2014 Oct;8:45-53. doi: 10.1016/j.coviro.2014.06.002. Epub 2014 Jul 2.</citation>
    <PMID>24997250</PMID>
  </reference>
  <reference>
    <citation>Al-Tawfiq JA, Hinedi K, Ghandour J, Khairalla H, Musleh S, Ujayli A, Memish ZA. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis. 2014 Jul 15;59(2):160-5. doi: 10.1093/cid/ciu226. Epub 2014 Apr 9.</citation>
    <PMID>24723278</PMID>
  </reference>
  <reference>
    <citation>Baez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015 Mar;115:21-38. doi: 10.1016/j.antiviral.2014.12.015. Epub 2014 Dec 29.</citation>
    <PMID>25554382</PMID>
  </reference>
  <reference>
    <citation>Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD. Broad-spectrum antiviral therapeutics. PLoS One. 2011;6(7):e22572. doi: 10.1371/journal.pone.0022572. Epub 2011 Jul 27.</citation>
    <PMID>21818340</PMID>
  </reference>
  <reference>
    <citation>Lundin A, Dijkman R, Bergstrom T, Kann N, Adamiak B, Hannoun C, Kindler E, Jonsdottir HR, Muth D, Kint J, Forlenza M, Muller MA, Drosten C, Thiel V, Trybala E. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus. PLoS Pathog. 2014 May 29;10(5):e1004166. doi: 10.1371/journal.ppat.1004166. eCollection 2014 May.</citation>
    <PMID>24874215</PMID>
  </reference>
  <reference>
    <citation>Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013 Dec;87(23):12552-61. doi: 10.1128/JVI.01890-13. Epub 2013 Sep 11.</citation>
    <PMID>24027332</PMID>
  </reference>
  <reference>
    <citation>Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9. doi: 10.1073/pnas.1407087111. Epub 2014 Oct 6.</citation>
    <PMID>25288733</PMID>
  </reference>
  <reference>
    <citation>Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 2015 Apr;28(2):465-522. doi: 10.1128/CMR.00102-14.</citation>
    <PMID>25810418</PMID>
  </reference>
  <reference>
    <citation>Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.</citation>
    <PMID>32004427</PMID>
  </reference>
  <reference>
    <citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4. No abstract available.</citation>
    <PMID>32020029</PMID>
  </reference>
  <reference>
    <citation>Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.</citation>
    <PMID>31986261</PMID>
  </reference>
  <reference>
    <citation>Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirglmaier K, Zange S, Wolfel R, Hoelscher M. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-971. doi: 10.1056/NEJMc2001468. Epub 2020 Jan 30. No abstract available.</citation>
    <PMID>32003551</PMID>
  </reference>
  <reference>
    <citation>Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.</citation>
    <PMID>31995857</PMID>
  </reference>
  <reference>
    <citation>Cheng RZ. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? Med Drug Discov. 2020 Mar;5:100028. doi: 10.1016/j.medidd.2020.100028. Epub 2020 Mar 26. No abstract available.</citation>
    <PMID>32328576</PMID>
  </reference>
  <reference>
    <citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.</citation>
    <PMID>31978945</PMID>
  </reference>
  <reference>
    <citation>Killerby ME, Biggs HM, Midgley CM, Gerber SI, Watson JT. Middle East Respiratory Syndrome Coronavirus Transmission. Emerg Infect Dis. 2020 Feb;26(2):191-198. doi: 10.3201/eid2602.190697.</citation>
    <PMID>31961300</PMID>
  </reference>
  <reference>
    <citation>Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. doi: 10.1038/s41467-019-13940-6.</citation>
    <PMID>31924756</PMID>
  </reference>
  <reference>
    <citation>Hijawi B, Abdallat M, Sayaydeh A, Alqasrawi S, Haddadin A, Jaarour N, Alsheikh S, Alsanouri T. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J. 2013;19 Suppl 1:S12-8.</citation>
    <PMID>23888790</PMID>
  </reference>
  <reference>
    <citation>de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013 Jul;87(14):7790-2. doi: 10.1128/JVI.01244-13. Epub 2013 May 15. No abstract available.</citation>
    <PMID>23678167</PMID>
  </reference>
  <reference>
    <citation>Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, Xiong J, Hawkey PM. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003 Aug;52(Pt 8):715-720. doi: 10.1099/jmm.0.05320-0.</citation>
    <PMID>12867568</PMID>
  </reference>
  <reference>
    <citation>Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, Sheng J, Quan L, Xia Z, Tan W, Cheng G, Jiang T. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020 Mar 11;27(3):325-328. doi: 10.1016/j.chom.2020.02.001. Epub 2020 Feb 7.</citation>
    <PMID>32035028</PMID>
  </reference>
  <reference>
    <citation>Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.</citation>
    <PMID>32007145</PMID>
  </reference>
  <reference>
    <citation>Lau SKP, Zhang L, Luk HKH, Xiong L, Peng X, Li KSM, He X, Zhao PS, Fan RYY, Wong ACP, Ahmed SS, Cai JP, Chan JFW, Sun Y, Jin D, Chen H, Lau TCK, Kok RKH, Li W, Yuen KY, Woo PCY. Receptor Usage of a Novel Bat Lineage C Betacoronavirus Reveals Evolution of Middle East Respiratory Syndrome-Related Coronavirus Spike Proteins for Human Dipeptidyl Peptidase 4 Binding. J Infect Dis. 2018 Jun 20;218(2):197-207. doi: 10.1093/infdis/jiy018.</citation>
    <PMID>29346682</PMID>
  </reference>
  <reference>
    <citation>Lau SK, Li KS, Tsang AK, Lam CS, Ahmed S, Chen H, Chan KH, Woo PC, Yuen KY. Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. J Virol. 2013 Aug;87(15):8638-50. doi: 10.1128/JVI.01055-13. Epub 2013 May 29.</citation>
    <PMID>23720729</PMID>
  </reference>
  <reference>
    <citation>Chu DKW, Hui KPY, Perera RAPM, Miguel E, Niemeyer D, Zhao J, Channappanavar R, Dudas G, Oladipo JO, Traore A, Fassi-Fihri O, Ali A, Demissie GF, Muth D, Chan MCW, Nicholls JM, Meyerholz DK, Kuranga SA, Mamo G, Zhou Z, So RTY, Hemida MG, Webby RJ, Roger F, Rambaut A, Poon LLM, Perlman S, Drosten C, Chevalier V, Peiris M. MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity. Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3144-3149. doi: 10.1073/pnas.1718769115. Epub 2018 Mar 5.</citation>
    <PMID>29507189</PMID>
  </reference>
  <reference>
    <citation>Paden CR, Yusof MFBM, Al Hammadi ZM, Queen K, Tao Y, Eltahir YM, Elsayed EA, Marzoug BA, Bensalah OKA, Khalafalla AI, Al Mulla M, Khudhair A, Elkheir KA, Issa ZB, Pradeep K, Elsaleh FN, Imambaccus H, Sasse J, Weber S, Shi M, Zhang J, Li Y, Pham H, Kim L, Hall AJ, Gerber SI, Al Hosani FI, Tong S, Al Muhairi SSM. Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE. Zoonoses Public Health. 2018 May;65(3):322-333. doi: 10.1111/zph.12435. Epub 2017 Dec 13.</citation>
    <PMID>29239118</PMID>
  </reference>
  <reference>
    <citation>Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, Zhang J, McEachern J, Field H, Daszak P, Eaton BT, Zhang S, Wang LF. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005 Oct 28;310(5748):676-9. doi: 10.1126/science.1118391. Epub 2005 Sep 29.</citation>
    <PMID>16195424</PMID>
  </reference>
  <reference>
    <citation>Hu B, Zeng LP, Yang XL, Ge XY, Zhang W, Li B, Xie JZ, Shen XR, Zhang YZ, Wang N, Luo DS, Zheng XS, Wang MN, Daszak P, Wang LF, Cui J, Shi ZL. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog. 2017 Nov 30;13(11):e1006698. doi: 10.1371/journal.ppat.1006698. eCollection 2017 Nov.</citation>
    <PMID>29190287</PMID>
  </reference>
  <reference>
    <citation>Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, Wong SS, Leung SY, Chan KH, Yuen KY. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5. doi: 10.1073/pnas.0506735102. Epub 2005 Sep 16.</citation>
    <PMID>16169905</PMID>
  </reference>
  <reference>
    <citation>Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, Lei LC, Chen QX, Gao YW, Zhou HQ, Xiang H, Zheng HJ, Chern SW, Cheng F, Pan CM, Xuan H, Chen SJ, Luo HM, Zhou DH, Liu YF, He JF, Qin PZ, Li LH, Ren YQ, Liang WJ, Yu YD, Anderson L, Wang M, Xu RH, Wu XW, Zheng HY, Chen JD, Liang G, Gao Y, Liao M, Fang L, Jiang LY, Li H, Chen F, Di B, He LJ, Lin JY, Tong S, Kong X, Du L, Hao P, Tang H, Bernini A, Yu XJ, Spiga O, Guo ZM, Pan HY, He WZ, Manuguerra JC, Fontanet A, Danchin A, Niccolai N, Li YX, Wu CI, Zhao GP. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5. doi: 10.1073/pnas.0409608102. Epub 2005 Feb 4.</citation>
    <PMID>15695582</PMID>
  </reference>
  <reference>
    <citation>Wang M, Xu HF, Zhang ZB, Zou XZ, Gao Y, Liu XN, Lu EJ, Liang CY, Pan BY, Wu SJ. [Analysis on the risk factors of severe acute respiratory syndromes coronavirus infection in workers from animal markets]. Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Jun;25(6):503-5. Chinese.</citation>
    <PMID>15231128</PMID>
  </reference>
  <reference>
    <citation>Forni D, Cagliani R, Clerici M, Sironi M. Molecular Evolution of Human Coronavirus Genomes. Trends Microbiol. 2017 Jan;25(1):35-48. doi: 10.1016/j.tim.2016.09.001. Epub 2016 Oct 19.</citation>
    <PMID>27743750</PMID>
  </reference>
  <reference>
    <citation>Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016 Jun;24(6):490-502. doi: 10.1016/j.tim.2016.03.003. Epub 2016 Mar 21.</citation>
    <PMID>27012512</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;:</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Ithete NL, Stoffberg S, Corman VM, Cottontail VM, Richards LR, Schoeman MC, Drosten C, Drexler JF, Preiser W. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis. 2013 Oct;19(10):1697-9. doi: 10.3201/eid1910.130946. No abstract available.</citation>
    <PMID>24050621</PMID>
  </reference>
  <reference>
    <citation>Sarris J, Kavanagh DJ. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med. 2009 Aug;15(8):827-36. doi: 10.1089/acm.2009.0066.</citation>
    <PMID>19614563</PMID>
  </reference>
  <reference>
    <citation>Alagaili AN, Briese T, Mishra N, Kapoor V, Sameroff SC, Burbelo PD, de Wit E, Munster VJ, Hensley LE, Zalmout IS, Kapoor A, Epstein JH, Karesh WB, Daszak P, Mohammed OB, Lipkin WI. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio. 2014 Feb 25;5(2):e00884-14. doi: 10.1128/mBio.00884-14. Erratum In: MBio. 2014;5(2):e01002-14. Burbelo, Peter D [added].</citation>
    <PMID>24570370</PMID>
  </reference>
  <reference>
    <citation>Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen KY, Peiris JS, Poon LL. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003 Oct 10;302(5643):276-8. doi: 10.1126/science.1087139. Epub 2003 Sep 4.</citation>
    <PMID>12958366</PMID>
  </reference>
  <reference>
    <citation>Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3. Erratum In: Nature. 2020 Dec;588(7836):E6.</citation>
    <PMID>32015507</PMID>
  </reference>
  <reference>
    <citation>Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013 Mar 14;495(7440):251-4. doi: 10.1038/nature12005.</citation>
    <PMID>23486063</PMID>
  </reference>
  <reference>
    <citation>Qian Z, Travanty EA, Oko L, Edeen K, Berglund A, Wang J, Ito Y, Holmes KV, Mason RJ. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. Am J Respir Cell Mol Biol. 2013 Jun;48(6):742-8. doi: 10.1165/rcmb.2012-0339OC.</citation>
    <PMID>23418343</PMID>
  </reference>
  <reference>
    <citation>Ji W, Li X. Response to comments on &quot;Cross-species Transmission of the Newly Identified Coronavirus 2019-nCoV&quot; and &quot;Codon bias analysis may be insufficient for identifying host(s) of a novel virus&quot;. J Med Virol. 2020 Sep;92(9):1440. doi: 10.1002/jmv.26048. Epub 2020 Jul 14. No abstract available.</citation>
    <PMID>32437080</PMID>
  </reference>
  <reference>
    <citation>Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020 Feb;91:264-266. doi: 10.1016/j.ijid.2020.01.009. Epub 2020 Jan 14. No abstract available.</citation>
    <PMID>31953166</PMID>
  </reference>
  <reference>
    <citation>Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020 Apr;92(4):418-423. doi: 10.1002/jmv.25681. Epub 2020 Feb 7. Erratum In: J Med Virol. 2020 Oct;92(10):2249.</citation>
    <PMID>31967327</PMID>
  </reference>
  <reference>
    <citation>Khan S, Nabi G, Han G, Siddique R, Lian S, Shi H, Bashir N, Ali A, Shereen MA. Novel coronavirus: how things are in Wuhan. Clin Microbiol Infect. 2020 Apr;26(4):399-400. doi: 10.1016/j.cmi.2020.02.005. Epub 2020 Feb 11. No abstract available.</citation>
    <PMID>32058086</PMID>
  </reference>
  <reference>
    <citation>Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012 Nov 8;367(19):1814-20. doi: 10.1056/NEJMoa1211721. Epub 2012 Oct 17. Erratum In: N Engl J Med. 2013 Jul 25;369(4):394.</citation>
    <PMID>23075143</PMID>
  </reference>
  <reference>
    <citation>Bawazir A, Al-Mazroo E, Jradi H, Ahmed A, Badri M. MERS-CoV infection: Mind the public knowledge gap. J Infect Public Health. 2018 Jan-Feb;11(1):89-93. doi: 10.1016/j.jiph.2017.05.003. Epub 2017 Jun 21.</citation>
    <PMID>28647126</PMID>
  </reference>
  <reference>
    <citation>Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, Li PH, Tan SY, Chang Q, Xie JP, Liu XQ, Xu J, Li DX, Yuen KY, Peiris, Guan Y. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003 Oct 25;362(9393):1353-8. doi: 10.1016/s0140-6736(03)14630-2.</citation>
    <PMID>14585636</PMID>
  </reference>
  <reference>
    <citation>Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019 Mar;17(3):181-192. doi: 10.1038/s41579-018-0118-9.</citation>
    <PMID>30531947</PMID>
  </reference>
  <reference>
    <citation>Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020 Feb 29;395(10225):689-697. doi: 10.1016/S0140-6736(20)30260-9. Epub 2020 Jan 31. Erratum In: Lancet. 2020 Feb 4;:</citation>
    <PMID>32014114</PMID>
  </reference>
  <reference>
    <citation>Kim K, Andrew SA, Jung K. Public Health Network Structure and Collaboration Effectiveness during the 2015 MERS Outbreak in South Korea: An Institutional Collective Action Framework. Int J Environ Res Public Health. 2017 Sep 15;14(9):1064. doi: 10.3390/ijerph14091064.</citation>
    <PMID>28914780</PMID>
  </reference>
  <reference>
    <citation>Malave A, Elamin EM. Severe Acute Respiratory Syndrome (SARS)-Lessons for Future Pandemics. Virtual Mentor. 2010 Sep 1;12(9):719-25. doi: 10.1001/virtualmentor.2010.12.9.cprl1-1009. No abstract available.</citation>
    <PMID>23186878</PMID>
  </reference>
  <reference>
    <citation>Park JE, Jung S, Kim A, Park JE. MERS transmission and risk factors: a systematic review. BMC Public Health. 2018 May 2;18(1):574. doi: 10.1186/s12889-018-5484-8.</citation>
    <PMID>29716568</PMID>
  </reference>
  <reference>
    <citation>Al-Tawfiq JA, Auwaerter PG. Healthcare-associated infections: the hallmark of Middle East respiratory syndrome coronavirus with review of the literature. J Hosp Infect. 2019 Jan;101(1):20-29. doi: 10.1016/j.jhin.2018.05.021. Epub 2018 Jun 1.</citation>
    <PMID>29864486</PMID>
  </reference>
  <reference>
    <citation>Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020 Feb 25;323(8):707-708. doi: 10.1001/jama.2020.0757. No abstract available.</citation>
    <PMID>31971553</PMID>
  </reference>
  <reference>
    <citation>Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandourah Y, Almekhlafi GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qushmaq I, Al Bshabshe A, Kharaba A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA; And the MIRACLE trial group. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018 Jan 30;19(1):81. doi: 10.1186/s13063-017-2427-0.</citation>
    <PMID>29382391</PMID>
  </reference>
  <reference>
    <citation>Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4956-4961. doi: 10.26355/eurrev_201808_15635.</citation>
    <PMID>30070331</PMID>
  </reference>
  <reference>
    <citation>Kim KH, Tandi TE, Choi JW, Moon JM, Kim MS. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect. 2017 Feb;95(2):207-213. doi: 10.1016/j.jhin.2016.10.008. Epub 2016 Oct 14.</citation>
    <PMID>28153558</PMID>
  </reference>
  <reference>
    <citation>Al-Omari A, Rabaan AA, Salih S, Al-Tawfiq JA, Memish ZA. MERS coronavirus outbreak: Implications for emerging viral infections. Diagn Microbiol Infect Dis. 2019 Mar;93(3):265-285. doi: 10.1016/j.diagmicrobio.2018.10.011. Epub 2018 Oct 18.</citation>
    <PMID>30413355</PMID>
  </reference>
  <reference>
    <citation>de Araujo Lopes A, da Fonseca FN, Rocha TM, de Freitas LB, Araujo EVO, Wong DVT, Lima Junior RCP, Leal LKAM. Eugenol as a Promising Molecule for the Treatment of Dermatitis: Antioxidant and Anti-inflammatory Activities and Its Nanoformulation. Oxid Med Cell Longev. 2018 Dec 11;2018:8194849. doi: 10.1155/2018/8194849. eCollection 2018.</citation>
    <PMID>30647816</PMID>
  </reference>
  <reference>
    <citation>Bachiega TF, de Sousa JP, Bastos JK, Sforcin JM. Clove and eugenol in noncytotoxic concentrations exert immunomodulatory/anti-inflammatory action on cytokine production by murine macrophages. J Pharm Pharmacol. 2012 Apr;64(4):610-6. doi: 10.1111/j.2042-7158.2011.01440.x. Epub 2012 Feb 7.</citation>
    <PMID>22420667</PMID>
  </reference>
  <reference>
    <citation>Kim SS, Oh OJ, Min HY, Park EJ, Kim Y, Park HJ, Nam Han Y, Lee SK. Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells. Life Sci. 2003 Jun 6;73(3):337-48. doi: 10.1016/s0024-3205(03)00288-1.</citation>
    <PMID>12757841</PMID>
  </reference>
  <reference>
    <citation>Yogalakshmi B, Viswanathan P, Anuradha CV. Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats. Toxicology. 2010 Feb 9;268(3):204-12. doi: 10.1016/j.tox.2009.12.018. Epub 2009 Dec 29. Erratum In: Toxicology. 2021 May 30;456:152781.</citation>
    <PMID>20036707</PMID>
  </reference>
  <reference>
    <citation>Mnafgui K, Hajji R, Derbali F, Gammoudi A, Khabbabi G, Ellefi H, Allouche N, Kadri A, Gharsallah N. Anti-inflammatory, Antithrombotic and Cardiac Remodeling Preventive Effects of Eugenol in Isoproterenol-Induced Myocardial Infarction in Wistar Rat. Cardiovasc Toxicol. 2016 Oct;16(4):336-44. doi: 10.1007/s12012-015-9343-x.</citation>
    <PMID>26391896</PMID>
  </reference>
  <reference>
    <citation>Pan C, Dong Z. Antiasthmatic Effects of Eugenol in a Mouse Model of Allergic Asthma by Regulation of Vitamin D3 Upregulated Protein 1/NF-kappaB Pathway. Inflammation. 2015 Aug;38(4):1385-93. doi: 10.1007/s10753-015-0110-8.</citation>
    <PMID>25588851</PMID>
  </reference>
  <reference>
    <citation>Abuohashish HM, Khairy DA, Abdelsalam MM, Alsayyah A, Ahmed MM, Al-Rejaie SS. In-vivo assessment of the osteo-protective effects of eugenol in alveolar bone tissues. Biomed Pharmacother. 2018 Jan;97:1303-1310. doi: 10.1016/j.biopha.2017.11.068. Epub 2017 Dec 14.</citation>
    <PMID>29156519</PMID>
  </reference>
  <reference>
    <citation>Deepak V, Kasonga A, Kruger MC, Coetzee M. Inhibitory effects of eugenol on RANKL-induced osteoclast formation via attenuation of NF-kappaB and MAPK pathways. Connect Tissue Res. 2015 Jun;56(3):195-203. doi: 10.3109/03008207.2014.989320. Epub 2014 Dec 11.</citation>
    <PMID>25405641</PMID>
  </reference>
  <reference>
    <citation>Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative Stress and Inflammation: What Polyphenols Can Do for Us? Oxid Med Cell Longev. 2016;2016:7432797. doi: 10.1155/2016/7432797. Epub 2016 Sep 22.</citation>
    <PMID>27738491</PMID>
  </reference>
  <reference>
    <citation>Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010 Dec 1;49(11):1603-16. doi: 10.1016/j.freeradbiomed.2010.09.006. Epub 2010 Sep 16.</citation>
    <PMID>20840865</PMID>
  </reference>
  <reference>
    <citation>Ambade A, Mandrekar P. Oxidative stress and inflammation: essential partners in alcoholic liver disease. Int J Hepatol. 2012;2012:853175. doi: 10.1155/2012/853175. Epub 2012 Mar 1.</citation>
    <PMID>22500241</PMID>
  </reference>
  <reference>
    <citation>Garcia N, Zazueta C, Aguilera-Aguirre L. Oxidative Stress and Inflammation in Cardiovascular Disease. Oxid Med Cell Longev. 2017;2017:5853238. doi: 10.1155/2017/5853238. Epub 2017 Apr 27. No abstract available.</citation>
    <PMID>28536646</PMID>
  </reference>
  <reference>
    <citation>Capasso A. Antioxidant action and therapeutic efficacy of Allium sativum L. Molecules. 2013 Jan 4;18(1):690-700. doi: 10.3390/molecules18010690.</citation>
    <PMID>23292331</PMID>
  </reference>
  <reference>
    <citation>Gu X, Wu H, Fu P. Allicin attenuates inflammation and suppresses HLA-B27 protein expression in ankylosing spondylitis mice. Biomed Res Int. 2013;2013:171573. doi: 10.1155/2013/171573. Epub 2013 Nov 13.</citation>
    <PMID>24324956</PMID>
  </reference>
  <reference>
    <citation>Ban JO, Yuk DY, Woo KS, Kim TM, Lee US, Jeong HS, Kim DJ, Chung YB, Hwang BY, Oh KW, Hong JT. Inhibition of cell growth and induction of apoptosis via inactivation of NF-kappaB by a sulfurcompound isolated from garlic in human colon cancer cells. J Pharmacol Sci. 2007 Aug;104(4):374-83. doi: 10.1254/jphs.fp0070789.</citation>
    <PMID>17721042</PMID>
  </reference>
  <reference>
    <citation>Macpherson LJ, Geierstanger BH, Viswanath V, Bandell M, Eid SR, Hwang S, Patapoutian A. The pungency of garlic: activation of TRPA1 and TRPV1 in response to allicin. Curr Biol. 2005 May 24;15(10):929-34. doi: 10.1016/j.cub.2005.04.018.</citation>
    <PMID>15916949</PMID>
  </reference>
  <reference>
    <citation>Alpers DH. Garlic and its potential for prevention of colorectal cancer and other conditions. Curr Opin Gastroenterol. 2009 Mar;25(2):116-21. doi: 10.1097/MOG.0b013e32831ef221. No abstract available.</citation>
    <PMID>19528879</PMID>
  </reference>
  <reference>
    <citation>Shen Y, Jia LN, Honma N, Hosono T, Ariga T, Seki T. Beneficial effects of cinnamon on the metabolic syndrome, inflammation, and pain, and mechanisms underlying these effects - a review. J Tradit Complement Med. 2012 Jan;2(1):27-32. doi: 10.1016/s2225-4110(16)30067-0.</citation>
    <PMID>24716111</PMID>
  </reference>
  <reference>
    <citation>Ta CA, Arnason JT. Mini Review of Phytochemicals and Plant Taxa with Activity as Microbial Biofilm and Quorum Sensing Inhibitors. Molecules. 2015 Dec 26;21(1):E29. doi: 10.3390/molecules21010029.</citation>
    <PMID>26712734</PMID>
  </reference>
  <reference>
    <citation>Anand David AV, Arulmoli R, Parasuraman S. Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid. Pharmacogn Rev. 2016 Jul-Dec;10(20):84-89. doi: 10.4103/0973-7847.194044.</citation>
    <PMID>28082789</PMID>
  </reference>
  <reference>
    <citation>Senchina DS, Hallam JE, Dias AS, Perera MA. Human blood mononuclear cell in vitro cytokine response before and after two different strenuous exercise bouts in the presence of bloodroot and Echinacea extracts. Blood Cells Mol Dis. 2009 Nov-Dec;43(3):298-303. doi: 10.1016/j.bcmd.2009.08.003. Epub 2009 Sep 19.</citation>
    <PMID>19766513</PMID>
  </reference>
  <reference>
    <citation>Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol. 1997 Jul;19(7):371-9. doi: 10.1016/s0192-0561(97)00061-1.</citation>
    <PMID>9568541</PMID>
  </reference>
  <reference>
    <citation>Ma XL, Meng M, Han LR, Li Z, Cao XH, Wang CL. Immunomodulatory activity of macromolecular polysaccharide isolated from Grifola frondosa. Chin J Nat Med. 2015 Dec;13(12):906-14. doi: 10.1016/S1875-5364(15)30096-0.</citation>
    <PMID>26721709</PMID>
  </reference>
  <reference>
    <citation>Tulk SE, Liao KC, Muruve DA, Li Y, Beck PL, MacDonald JA. Vitamin D(3) metabolites enhance the NLRP3-dependent secretion of IL-1beta from human THP-1 monocytic cells. J Cell Biochem. 2015 May;116(5):711-20. doi: 10.1002/jcb.24985.</citation>
    <PMID>25639477</PMID>
  </reference>
  <reference>
    <citation>Verway M, Bouttier M, Wang TT, Carrier M, Calderon M, An BS, Devemy E, McIntosh F, Divangahi M, Behr MA, White JH. Vitamin D induces interleukin-1beta expression: paracrine macrophage epithelial signaling controls M. tuberculosis infection. PLoS Pathog. 2013;9(6):e1003407. doi: 10.1371/journal.ppat.1003407. Epub 2013 Jun 6.</citation>
    <PMID>23762029</PMID>
  </reference>
  <reference>
    <citation>Rao Z, Chen X, Wu J, Xiao M, Zhang J, Wang B, Fang L, Zhang H, Wang X, Yang S, Chen Y. Vitamin D Receptor Inhibits NLRP3 Activation by Impeding Its BRCC3-Mediated Deubiquitination. Front Immunol. 2019 Dec 4;10:2783. doi: 10.3389/fimmu.2019.02783. eCollection 2019.</citation>
    <PMID>31866999</PMID>
  </reference>
  <reference>
    <citation>Lu L, Lu Q, Chen W, Li J, Li C, Zheng Z. Vitamin D3 Protects against Diabetic Retinopathy by Inhibiting High-Glucose-Induced Activation of the ROS/TXNIP/NLRP3 Inflammasome Pathway. J Diabetes Res. 2018 Feb 22;2018:8193523. doi: 10.1155/2018/8193523. eCollection 2018.</citation>
    <PMID>29682582</PMID>
  </reference>
  <reference>
    <citation>Ulbricht C, Basch E, Cheung L, Goldberg H, Hammerness P, Isaac R, Khalsa KP, Romm A, Rychlik I, Varghese M, Weissner W, Windsor RC, Wortley J. An evidence-based systematic review of elderberry and elderflower (Sambucus nigra) by the Natural Standard Research Collaboration. J Diet Suppl. 2014 Mar;11(1):80-120. doi: 10.3109/19390211.2013.859852. Epub 2014 Jan 10.</citation>
    <PMID>24409980</PMID>
  </reference>
  <reference>
    <citation>Chen C, Zuckerman DM, Brantley S, Sharpe M, Childress K, Hoiczyk E, Pendleton AR. Sambucus nigra extracts inhibit infectious bronchitis virus at an early point during replication. BMC Vet Res. 2014 Jan 16;10:24. doi: 10.1186/1746-6148-10-24.</citation>
    <PMID>24433341</PMID>
  </reference>
  <reference>
    <citation>Weng JR, Lin CS, Lai HC, Lin YP, Wang CY, Tsai YC, Wu KC, Huang SH, Lin CW. Antiviral activity of Sambucus FormosanaNakai ethanol extract and related phenolic acid constituents against human coronavirus NL63. Virus Res. 2019 Nov;273:197767. doi: 10.1016/j.virusres.2019.197767. Epub 2019 Sep 24.</citation>
    <PMID>31560964</PMID>
  </reference>
  <reference>
    <citation>Hemila H. Vitamin C supplementation and respiratory infections: a systematic review. Mil Med. 2004 Nov;169(11):920-5. doi: 10.7205/milmed.169.11.920.</citation>
    <PMID>15605943</PMID>
  </reference>
  <reference>
    <citation>Choe JY, Kim SK. Quercetin and Ascorbic Acid Suppress Fructose-Induced NLRP3 Inflammasome Activation by Blocking Intracellular Shuttling of TXNIP in Human Macrophage Cell Lines. Inflammation. 2017 Jun;40(3):980-994. doi: 10.1007/s10753-017-0542-4.</citation>
    <PMID>28326454</PMID>
  </reference>
  <reference>
    <citation>Dabbagh-Bazarbachi H, Clergeaud G, Quesada IM, Ortiz M, O'Sullivan CK, Fernandez-Larrea JB. Zinc ionophore activity of quercetin and epigallocatechin-gallate: from Hepa 1-6 cells to a liposome model. J Agric Food Chem. 2014 Aug 13;62(32):8085-93. doi: 10.1021/jf5014633. Epub 2014 Jul 31.</citation>
    <PMID>25050823</PMID>
  </reference>
  <reference>
    <citation>Kaihatsu K, Yamabe M, Ebara Y. Antiviral Mechanism of Action of Epigallocatechin-3-O-gallate and Its Fatty Acid Esters. Molecules. 2018 Sep 27;23(10):2475. doi: 10.3390/molecules23102475.</citation>
    <PMID>30262731</PMID>
  </reference>
  <reference>
    <citation>Wen CC, Kuo YH, Jan JT, Liang PH, Wang SY, Liu HG, Lee CK, Chang ST, Kuo CJ, Lee SS, Hou CC, Hsiao PW, Chien SC, Shyur LF, Yang NS. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007 Aug 23;50(17):4087-95. doi: 10.1021/jm070295s. Epub 2007 Jul 31.</citation>
    <PMID>17663539</PMID>
  </reference>
  <reference>
    <citation>Chen H, Lin H, Xie S, Huang B, Qian Y, Chen K, Niu Y, Shen HM, Cai J, Li P, Leng J, Yang H, Xia D, Wu Y. Myricetin inhibits NLRP3 inflammasome activation via reduction of ROS-dependent ubiquitination of ASC and promotion of ROS-independent NLRP3 ubiquitination. Toxicol Appl Pharmacol. 2019 Feb 15;365:19-29. doi: 10.1016/j.taap.2018.12.019. Epub 2018 Dec 27.</citation>
    <PMID>30594691</PMID>
  </reference>
  <reference>
    <citation>Yamagata K, Hashiguchi K, Yamamoto H, Tagami M. Dietary Apigenin Reduces Induction of LOX-1 and NLRP3 Expression, Leukocyte Adhesion, and Acetylated Low-Density Lipoprotein Uptake in Human Endothelial Cells Exposed to Trimethylamine-N-Oxide. J Cardiovasc Pharmacol. 2019 Dec;74(6):558-565. doi: 10.1097/FJC.0000000000000747.</citation>
    <PMID>31815868</PMID>
  </reference>
  <reference>
    <citation>Lim H, Min DS, Park H, Kim HP. Flavonoids interfere with NLRP3 inflammasome activation. Toxicol Appl Pharmacol. 2018 Sep 15;355:93-102. doi: 10.1016/j.taap.2018.06.022. Epub 2018 Jun 28.</citation>
    <PMID>29960001</PMID>
  </reference>
  <reference>
    <citation>Phillips JM, Gallagher T, Weiss SR. Neurovirulent Murine Coronavirus JHM.SD Uses Cellular Zinc Metalloproteases for Virus Entry and Cell-Cell Fusion. J Virol. 2017 Mar 29;91(8):e01564-16. doi: 10.1128/JVI.01564-16. Print 2017 Apr 15.</citation>
    <PMID>28148786</PMID>
  </reference>
  <reference>
    <citation>Romero JM, Grunwald B, Jang GH, Bavi PP, Jhaveri A, Masoomian M, Fischer SE, Zhang A, Denroche RE, Lungu IM, De Luca A, Bartlett JMS, Xu J, Li N, Dhaliwal S, Liang SB, Chadwick D, Vyas F, Bronsert P, Khokha R, McGaha TL, Notta F, Ohashi PS, Done SJ, O'Kane GM, Wilson JM, Knox JJ, Connor A, Wang Y, Zogopoulos G, Gallinger S. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. Clin Cancer Res. 2020 Apr 15;26(8):1997-2010. doi: 10.1158/1078-0432.CCR-19-2803. Epub 2020 Jan 21.</citation>
    <PMID>31964786</PMID>
  </reference>
  <reference>
    <citation>Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, Farber JM, Fairchild RL. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol. 2007 Feb 15;178(4):2278-86. doi: 10.4049/jimmunol.178.4.2278.</citation>
    <PMID>17277133</PMID>
  </reference>
  <reference>
    <citation>Prather AA, Janicki-Deverts D, Hall MH, Cohen S. Behaviorally Assessed Sleep and Susceptibility to the Common Cold. Sleep. 2015 Sep 1;38(9):1353-9. doi: 10.5665/sleep.4968.</citation>
    <PMID>26118561</PMID>
  </reference>
  <reference>
    <citation>Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.</citation>
    <PMID>32132184</PMID>
  </reference>
  <reference>
    <citation>Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q, Wu J. Coronavirus infections and immune responses. J Med Virol. 2020 Apr;92(4):424-432. doi: 10.1002/jmv.25685. Epub 2020 Feb 7.</citation>
    <PMID>31981224</PMID>
  </reference>
  <reference>
    <citation>He Y, Hara H, Nunez G. Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem Sci. 2016 Dec;41(12):1012-1021. doi: 10.1016/j.tibs.2016.09.002. Epub 2016 Sep 23.</citation>
    <PMID>27669650</PMID>
  </reference>
  <reference>
    <citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16. No abstract available.</citation>
    <PMID>32192578</PMID>
  </reference>
  <reference>
    <citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. No abstract available. Erratum In: Lancet Respir Med. 2020 Feb 25;:</citation>
    <PMID>32085846</PMID>
  </reference>
  <reference>
    <citation>Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 2014 Jun;1319(1):82-95. doi: 10.1111/nyas.12458. Epub 2014 May 19.</citation>
    <PMID>24840700</PMID>
  </reference>
  <reference>
    <citation>Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30. No abstract available.</citation>
    <PMID>32227760</PMID>
  </reference>
  <reference>
    <citation>Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 2005 Feb;45(2):163-9. doi: 10.1161/01.HYP.0000153321.13792.b9. Epub 2005 Jan 3.</citation>
    <PMID>15630047</PMID>
  </reference>
  <reference>
    <citation>Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020 May 14;181(4):905-913.e7. doi: 10.1016/j.cell.2020.04.004. Epub 2020 Apr 24.</citation>
    <PMID>32333836</PMID>
  </reference>
  <reference>
    <citation>Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, Smoot J, Gregg AC, Daniels AD, Jervey S, Albaiu D. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci. 2020 Mar 25;6(3):315-331. doi: 10.1021/acscentsci.0c00272. Epub 2020 Mar 12. No abstract available.</citation>
    <PMID>32226821</PMID>
  </reference>
  <reference>
    <citation>Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13.</citation>
    <PMID>32178769</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020 Mar 27;12(4):372. doi: 10.3390/v12040372.</citation>
    <PMID>32230900</PMID>
  </reference>
  <results_reference>
    <citation>Schindewolf C, Menachery VD. Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism. Viruses. 2019 Jan 17;11(1):74. doi: 10.3390/v11010074.</citation>
    <PMID>30658390</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 25, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Unidad de Investigación Genética Molecular</investigator_affiliation>
    <investigator_full_name>Beatriz Aristizabal</investigator_full_name>
    <investigator_title>Beatriz H Aristizabal B, MsC immunology, MsC Medical Genetics, PhD Molecular Biolgy, Scientific director of Unidad de Investigación Genética Molecular</investigator_title>
  </responsible_party>
  <keyword>Coronavirus Infections, Spike Glycoprotein, Functional Food, Triple Blind Clinical Study,Efficacy-Effectiveness of Interventions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adjuvants, Immunologic</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04420260
org study id: UNIGEM PT-IC-02
nct id: NCT04420260
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
is us export: No
Introduction: The SARS Co-2 contagious rate is high (Ro: 2.0-3.0). The infection is
      aggressive with high pathogenicity. Global confinement impacts all social and economic fields
      of human activity. Clinical behavior exceeds the capabilities of public health care. With the
      initial information on the pandemic, it is estimated that 20% of health personnel in direct
      contact with patients can acquire the disease, despite preventive self-care. The molecular
      relationship of COVID-19 with the subject's ACE2 protein encourages the virus to enter the
      host cell, and initiates replication and the immune response, causing an imbalance generating
      an immunological storm of cytokines, with serious damage to the host.

      Objective: It is proposed to supply a combined scheme of two compounds by oropharyngeal spray
      that captures the virus before entering the target cell and orally administer
      immunomodulatory compounds that regulate the inflammatory response released by the virus, in
      order to improve the antiviral response.

      Methodology: A controlled, parallel design, triple-blind, phase II clinical trial will be
      conducted with two study groups to compare the active compounds (oropharyngeal spray and
      emulsion) with placebo.

      Discussion: With the application of the combined scheme of two compounds, a 75% reduction in
      infection is expected for workers in direct contact with COVID patients.
RESEARCH QUESTION: Can the oropharyngeal spray of a viral blocking compound in conjunction
      with the provision of an immunostimulant emulsion, reduce the infection proportion by 2/3

      ACTIVE PRINCIPLE Intervention 1. BlockACE2® spray, antimicrobial and antiviral liquid
      solution for mouth spray, composed of 3 natural bioactive substances proven to be used in
      humans, which present molecular structures homologous to the native receptor of the virus. It
      contains binding peptides that resemble the ACE2 receptor, which bind to viral fractions, and
      acts as soluble scavengers of the virus at the entrance gate, upper respiratory tract, or
      oropharyngeal region, preventing its entry into the target cell and decreasing the amount of
      virus that enters the body; consequently, they reduce their ability to generate damage.

      BlockACE2® Defense, food for oral administration in the form of an emulsion with 8 bioactive
      components that have shown modulation of the inflammatory response. Contains natural oils,
      Vitamin B6, Vitamin C, Vitamin E, Vitamin D3 100 SD / S, and minerals; key micronutrients
      that are not normally obtained through a traditional diet. These nutrients are
      immunostimulants with proven capacity to enhance the cellular response against viruses,
      anti-inflammatory, antioxidant, and chemoprotective activity, stimulating the production of
      interferon I; and as a whole, they prevent the generation of an excessive immune activation
      process, known as an "immune storm" mediated by pro-inflammatory cytokines.

      Intervention 2, Placebo:

      Preparations without active components in the pharmaceutical form of the above (Intervention
      1 and Intervention 2). They will be presented with the same physical characteristics such as
      size, shape, color, taste, smell, consistency, printed signs, weight, surface finish,
      internal and external; in order to guarantee the principle of masking.

      RESEARCH HYPOTHESIS:

      In a population with community risk of COVID-19 infection, the combined use of the study
      interventions (the oral antimicrobial solution in Spray BlockACE2® and the food in BlockACE2®
      emulsion, compared to the use of Placebo, reduces the risk of COVID-19 infection expressed in
      a negative PCR result in those who seroconvert to IgM, and in those who seroconvert, the
      higher proportion will be in the mild-moderate clinical form.

      PRIMARY OBJECTIVE To establish the efficacy of the combined use of BlockACE2® oropharyngeal
      spray, and BlockACE2® emulsion, in comparison with placebo on the reduction of the risk of
      infection by COVID-19, expressed in the negative result of immunoglobulins for COVID-19 (30
      days from admission to the project).

      Establish the safety of the products under study by evaluating the expected and unexpected
      adverse events that are recorded during the use phase of the intervention scheme (30 days
      from project entry).

      SECONDARY OBJECTIVE To establish the efficacy of the combined use of BlockACE2® spray, a
      soluble virus scavenger compound plus ingestion of BlockACE2® emulsion, a compound that
      improves the defenses of the immune system, compared to placebo, on reducing the risk of
      infection by COVID-19 expressed in the clinical response of the disease that is defined in
      three variables, mild to moderate: onset of fever, myalgia, and cough without dyspnea;
      severe: fever, myalgia, cough and dyspnea requiring hospital care; and critical: all the
      above plus ventilatory assistance in ICU.

      EXPLORATORY OBJECTIVES Explore the efficacy of the combined use of BlockACE2® spray, a
      soluble virus scavenger compound, plus the intake of BlockACE2®, an emulsion food with key
      micronutrients that stimulate the antiviral cellular immune response on reducing the risk of
      COVID-19 infection expressed in the negative result of IgG, IgM; and the reduction of the
      risk of symptoms such as fever, cough, dyspnea, myalgia, or ventilatory assistance in the ICU
      after 15 days of finishing the scheme.

      FIELD OF STUDY: Workers of every department of Conconcreto Company in the city of Medellín
      and Girardota

      INTERVENTIONS:

      Intervention 1 BLOCKACE2: Two oropharyngeal sprays of the compound, every 4 hours, during the
      day. For the BlockACE2 emulsion will be used 20 ml during the first 5 days and after it only
      10ml every day for 30 days. Dosing of the substances in intervention 1 follows the described
      pharmacological characteristics, that guarantee its permanence in the oral mucosa to protect
      the entry pathway of the virus into the organism (Oropharynx). The dosage of the oral
      compounds was defined according to recommendations of the WHO for the modulation of the
      immune response (Emulsion).

      Intervention 2 PLACEBO: spray and emulsion with similar color, smell, and texture but without
      the natural active compounds.

      In the randomization visit V1, each participant will be assigned a treatment scheme, composed
      of intervention 1 and intervention 2, in sufficient quantity for the duration of the study.
      The pharmaceutical service will dispense the code of the scheme, following a sequential
      order, indicated in an allocation listing of the schemes on site. Each treatment scheme is
      labeled with a unique code that identifies it, and it contains One (1) device for
      oropharyngeal spray, with a capacity for 200 applications. One (1) bottle with 360 ml (oral).
      In the subsequent visits, the adherence to the dispensed schemes will be verified. The
      frequency of use will be checked, and dosing omissions will be registered by frequency (1
      dose, once a week, more than once a week).
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Combination of an oropharyngeal spray and an oral immunostimulant agent for the prevention of COVID-19 infection in workers in Medellín-Antioquia. The randomized clinical trial, parallel design, triple-blind, phase II.
Combination of an oropharyngeal spray and an oral immunostimulant agent for the prevention of COVID-19 infection in workers in Medellín-Antioquia. The randomized clinical trial, parallel design, triple-blind, phase II.
A two-arm is stipulated, in the following manner:
Group A: Active principle spray + Active principle emulsion. Group B: Placebo spray + Placebo emulsion.
primary purpose: Prevention
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
masking description: Once the participant has given its informed consent, and the research team has verified the fulfillment of the inclusion criteria, the prospect receives a text message, to be directed to the pharmaceutical service. The numbered scheme will be dispensed with the code of the intervention, following the order from the allocation listing, provided by the CTCC. The head of the pharmaceutical service will register the date and time of the first dose. He will provide indications for the use, handling, and conservation of the products. Warning signs and symptoms and instructions for communication with the research team to address any concerns the subject may have will be reviewed. He will remind the subject to avoid its damage or loss. He will give the participant instructions to return the container and surpluses of the products at the end of the trial (day 30), he will point out that they are for personal use only and that they cannot be shared.
measure: Seroconversion of IgM for COVID-19.
time frame: 1 month
description: Seroconversion of IgM for COVID-19. Result of positive IgM antibodies: A previously scheduled closure visit will be conducted, the trial product will be interrupted if a case is classified as severe-critical, and clinical follow up will be continued as planned. As protocols by the Health Ministry dictate, cases will be confirmed with a PCR-RT test, for the diagnosis of COVID-19. The result of the test will be requested to document the outcome.
measure: Seroconversion of IgG for COVID-19.
time frame: through study completion, 45 days
description: seroconversion of IgG
arm group label: Treatment oropharyngeal spray + immunostimulant emulsion
arm group type: Experimental
description: Active principle oropharyngeal spray + Active principle immunostimulant taken PO.
arm group label: Placebo
arm group type: Placebo Comparator
description: Placebo oropharyngeal spray + Placebo emulsion was taken PO.
intervention type: Dietary Supplement
intervention name: Group A: oropharygeal spray and immunostimulant emulsion
description: Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of 3 natural bioactive substances of routine use in humans, that feature homologous molecular structures to the native viral receptor.
Intervention 2. Preparation in an emulsion functional food presentation for oral administration, that contains the 8 bioactive compounds that have demonstrated antiviral activity and modulation of the inflammatory response recognized at the moment in the immune activation against the virus.
arm group label: Treatment oropharyngeal spray + immunostimulant emulsion
other name: BLOCKACE2 (oropharyngeal spray) + BLOCKACE2 Emulsion (Active principle immunostimulant )
intervention type: Dietary Supplement
intervention name: Group D:Placebo oropharyngeal spray + Placebo taken PO
description: Intervention 1: Preparation in a liquid solution to be used for oropharyngeal spray, composed of Placebo substances of routine use in humans.
Intervention 2. Preparation in an emulsion presentation for oral administration that contains the Placebo compounds
arm group label: Placebo
other name: Placebo+ Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 60 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Beatriz H Aristizabal, PhD
role: Principal Investigator
affiliation: Unidad de Investigación Genética Molecular
facility: 
country: Colombia
citation: Yong CY, Ong HK, Yeap SK, Ho KL, Tan WS. Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus. Front Microbiol. 2019 Aug 2;10:1781. doi: 10.3389/fmicb.2019.01781. eCollection 2019.
PMID: 31428074
citation: Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, Zhu H, Zhao W, Han Y, Qin C. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses. 2019 Jan 14;11(1):59. doi: 10.3390/v11010059.
PMID: 30646565
citation: Thomas SJ, L'Azou M, Barrett AD, Jackson NA. Fast-Track Zika Vaccine Development - Is It Possible? N Engl J Med. 2016 Sep 29;375(13):1212-6. doi: 10.1056/NEJMp1609300. No abstract available.
PMID: 27682032
citation: Koch S, Pong W, Editors. The count of companies developing vaccines for coronavirus rises 2020 [Internet]. Redwood: BioCentury; 2020 [cited 2020 Feb 16]. Available from: https://www.biocentury.com/article/304412
citation: Ma-Lauer Y, Zheng Y, Malesevic M, von Brunn B, Fischer G, von Brunn A. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Res. 2020 Jan;173:104620. doi: 10.1016/j.antiviral.2019.104620. Epub 2019 Oct 18.
PMID: 31634494
citation: Shakya A, Bhat HR, Ghosh SK. Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent. Curr Drug Discov Technol. 2018;15(3):201-213. doi: 10.2174/1570163814666170727130003.
PMID: 28748751
citation: Pervushin K, Tan E, Parthasarathy K, Lin X, Jiang FL, Yu D, Vararattanavech A, Soong TW, Liu DX, Torres J. Structure and inhibition of the SARS coronavirus envelope protein ion channel. PLoS Pathog. 2009 Jul;5(7):e1000511. doi: 10.1371/journal.ppat.1000511. Epub 2009 Jul 10.
PMID: 19593379
citation: Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A, Brock G, Montefiori DC, Vojdani F, McCormick AA, O'Keefe BR, Palmer KE. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother. 2014;58(1):120-7. doi: 10.1128/AAC.01407-13. Epub 2013 Oct 21.
PMID: 24145548
citation: Pruijssers AJ, Denison MR. Nucleoside analogues for the treatment of coronavirus infections. Curr Opin Virol. 2019 Apr;35:57-62. doi: 10.1016/j.coviro.2019.04.002. Epub 2019 May 21.
PMID: 31125806
citation: Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019 Apr;14(4):397-412. doi: 10.1080/17460441.2019.1581171. Epub 2019 Mar 8.
PMID: 30849247
citation: Mielech AM, Kilianski A, Baez-Santos YM, Mesecar AD, Baker SC. MERS-CoV papain-like protease has deISGylating and deubiquitinating activities. Virology. 2014 Feb;450-451:64-70. doi: 10.1016/j.virol.2013.11.040. Epub 2013 Dec 22.
PMID: 24503068
citation: Momattin H, Al-Ali AY, Al-Tawfiq JA. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Travel Med Infect Dis. 2019 Jul-Aug;30:9-18. doi: 10.1016/j.tmaid.2019.06.012. Epub 2019 Jun 25.
PMID: 31252170
citation: Sutton TC, Subbarao K. Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus. Virology. 2015 May;479-480:247-58. doi: 10.1016/j.virol.2015.02.030. Epub 2015 Mar 16.
PMID: 25791336
citation: Mubarak A, Alturaiki W, Hemida MG. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. J Immunol Res. 2019 Apr 7;2019:6491738. doi: 10.1155/2019/6491738. eCollection 2019.
PMID: 31089478
citation: Wiley JA, Richert LE, Swain SD, Harmsen A, Barnard DL, Randall TD, Jutila M, Douglas T, Broomell C, Young M, Harmsen A. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS One. 2009 Sep 23;4(9):e7142. doi: 10.1371/journal.pone.0007142.
PMID: 19774076
citation: Wohlford-Lenane CL, Meyerholz DK, Perlman S, Zhou H, Tran D, Selsted ME, McCray PB Jr. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J Virol. 2009 Nov;83(21):11385-90. doi: 10.1128/JVI.01363-09. Epub 2009 Aug 26.
PMID: 19710146
citation: Adedeji AO, Sarafianos SG. Antiviral drugs specific for coronaviruses in preclinical development. Curr Opin Virol. 2014 Oct;8:45-53. doi: 10.1016/j.coviro.2014.06.002. Epub 2014 Jul 2.
PMID: 24997250
citation: Al-Tawfiq JA, Hinedi K, Ghandour J, Khairalla H, Musleh S, Ujayli A, Memish ZA. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis. 2014 Jul 15;59(2):160-5. doi: 10.1093/cid/ciu226. Epub 2014 Apr 9.
PMID: 24723278
citation: Baez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015 Mar;115:21-38. doi: 10.1016/j.antiviral.2014.12.015. Epub 2014 Dec 29.
PMID: 25554382
citation: Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD. Broad-spectrum antiviral therapeutics. PLoS One. 2011;6(7):e22572. doi: 10.1371/journal.pone.0022572. Epub 2011 Jul 27.
PMID: 21818340
citation: Lundin A, Dijkman R, Bergstrom T, Kann N, Adamiak B, Hannoun C, Kindler E, Jonsdottir HR, Muth D, Kint J, Forlenza M, Muller MA, Drosten C, Thiel V, Trybala E. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus. PLoS Pathog. 2014 May 29;10(5):e1004166. doi: 10.1371/journal.ppat.1004166. eCollection 2014 May.
PMID: 24874215
citation: Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013 Dec;87(23):12552-61. doi: 10.1128/JVI.01890-13. Epub 2013 Sep 11.
PMID: 24027332
citation: Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9. doi: 10.1073/pnas.1407087111. Epub 2014 Oct 6.
PMID: 25288733
citation: Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev. 2015 Apr;28(2):465-522. doi: 10.1128/CMR.00102-14.
PMID: 25810418
citation: Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
PMID: 32004427
citation: Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4. No abstract available.
PMID: 32020029
citation: Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.
PMID: 31986261
citation: Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirglmaier K, Zange S, Wolfel R, Hoelscher M. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-971. doi: 10.1056/NEJMc2001468. Epub 2020 Jan 30. No abstract available.
PMID: 32003551
citation: Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JT, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-1207. doi: 10.1056/NEJMoa2001316. Epub 2020 Jan 29.
PMID: 31995857
citation: Cheng RZ. Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)? Med Drug Discov. 2020 Mar;5:100028. doi: 10.1016/j.medidd.2020.100028. Epub 2020 Mar 26. No abstract available.
PMID: 32328576
citation: Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
PMID: 31978945
citation: Killerby ME, Biggs HM, Midgley CM, Gerber SI, Watson JT. Middle East Respiratory Syndrome Coronavirus Transmission. Emerg Infect Dis. 2020 Feb;26(2):191-198. doi: 10.3201/eid2602.190697.
PMID: 31961300
citation: Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. doi: 10.1038/s41467-019-13940-6.
PMID: 31924756
citation: Hijawi B, Abdallat M, Sayaydeh A, Alqasrawi S, Haddadin A, Jaarour N, Alsheikh S, Alsanouri T. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J. 2013;19 Suppl 1:S12-8.
PMID: 23888790
citation: de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M, Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013 Jul;87(14):7790-2. doi: 10.1128/JVI.01244-13. Epub 2013 May 15. No abstract available.
PMID: 23678167
citation: Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, Xiong J, Hawkey PM. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003 Aug;52(Pt 8):715-720. doi: 10.1099/jmm.0.05320-0.
PMID: 12867568
citation: Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, Sheng J, Quan L, Xia Z, Tan W, Cheng G, Jiang T. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020 Mar 11;27(3):325-328. doi: 10.1016/j.chom.2020.02.001. Epub 2020 Feb 7.
PMID: 32035028
citation: Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
PMID: 32007145
citation: Lau SKP, Zhang L, Luk HKH, Xiong L, Peng X, Li KSM, He X, Zhao PS, Fan RYY, Wong ACP, Ahmed SS, Cai JP, Chan JFW, Sun Y, Jin D, Chen H, Lau TCK, Kok RKH, Li W, Yuen KY, Woo PCY. Receptor Usage of a Novel Bat Lineage C Betacoronavirus Reveals Evolution of Middle East Respiratory Syndrome-Related Coronavirus Spike Proteins for Human Dipeptidyl Peptidase 4 Binding. J Infect Dis. 2018 Jun 20;218(2):197-207. doi: 10.1093/infdis/jiy018.
PMID: 29346682
citation: Lau SK, Li KS, Tsang AK, Lam CS, Ahmed S, Chen H, Chan KH, Woo PC, Yuen KY. Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus. J Virol. 2013 Aug;87(15):8638-50. doi: 10.1128/JVI.01055-13. Epub 2013 May 29.
PMID: 23720729
citation: Chu DKW, Hui KPY, Perera RAPM, Miguel E, Niemeyer D, Zhao J, Channappanavar R, Dudas G, Oladipo JO, Traore A, Fassi-Fihri O, Ali A, Demissie GF, Muth D, Chan MCW, Nicholls JM, Meyerholz DK, Kuranga SA, Mamo G, Zhou Z, So RTY, Hemida MG, Webby RJ, Roger F, Rambaut A, Poon LLM, Perlman S, Drosten C, Chevalier V, Peiris M. MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity. Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3144-3149. doi: 10.1073/pnas.1718769115. Epub 2018 Mar 5.
PMID: 29507189
citation: Paden CR, Yusof MFBM, Al Hammadi ZM, Queen K, Tao Y, Eltahir YM, Elsayed EA, Marzoug BA, Bensalah OKA, Khalafalla AI, Al Mulla M, Khudhair A, Elkheir KA, Issa ZB, Pradeep K, Elsaleh FN, Imambaccus H, Sasse J, Weber S, Shi M, Zhang J, Li Y, Pham H, Kim L, Hall AJ, Gerber SI, Al Hosani FI, Tong S, Al Muhairi SSM. Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE. Zoonoses Public Health. 2018 May;65(3):322-333. doi: 10.1111/zph.12435. Epub 2017 Dec 13.
PMID: 29239118
citation: Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H, Zhang J, McEachern J, Field H, Daszak P, Eaton BT, Zhang S, Wang LF. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005 Oct 28;310(5748):676-9. doi: 10.1126/science.1118391. Epub 2005 Sep 29.
PMID: 16195424
citation: Hu B, Zeng LP, Yang XL, Ge XY, Zhang W, Li B, Xie JZ, Shen XR, Zhang YZ, Wang N, Luo DS, Zheng XS, Wang MN, Daszak P, Wang LF, Cui J, Shi ZL. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog. 2017 Nov 30;13(11):e1006698. doi: 10.1371/journal.ppat.1006698. eCollection 2017 Nov.
PMID: 29190287
citation: Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, Wong SS, Leung SY, Chan KH, Yuen KY. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5. doi: 10.1073/pnas.0506735102. Epub 2005 Sep 16.
PMID: 16169905
citation: Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, Lei LC, Chen QX, Gao YW, Zhou HQ, Xiang H, Zheng HJ, Chern SW, Cheng F, Pan CM, Xuan H, Chen SJ, Luo HM, Zhou DH, Liu YF, He JF, Qin PZ, Li LH, Ren YQ, Liang WJ, Yu YD, Anderson L, Wang M, Xu RH, Wu XW, Zheng HY, Chen JD, Liang G, Gao Y, Liao M, Fang L, Jiang LY, Li H, Chen F, Di B, He LJ, Lin JY, Tong S, Kong X, Du L, Hao P, Tang H, Bernini A, Yu XJ, Spiga O, Guo ZM, Pan HY, He WZ, Manuguerra JC, Fontanet A, Danchin A, Niccolai N, Li YX, Wu CI, Zhao GP. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5. doi: 10.1073/pnas.0409608102. Epub 2005 Feb 4.
PMID: 15695582
citation: Wang M, Xu HF, Zhang ZB, Zou XZ, Gao Y, Liu XN, Lu EJ, Liang CY, Pan BY, Wu SJ. [Analysis on the risk factors of severe acute respiratory syndromes coronavirus infection in workers from animal markets]. Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Jun;25(6):503-5. Chinese.
PMID: 15231128
citation: Forni D, Cagliani R, Clerici M, Sironi M. Molecular Evolution of Human Coronavirus Genomes. Trends Microbiol. 2017 Jan;25(1):35-48. doi: 10.1016/j.tim.2016.09.001. Epub 2016 Oct 19.
PMID: 27743750
citation: Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol. 2016 Jun;24(6):490-502. doi: 10.1016/j.tim.2016.03.003. Epub 2016 Mar 21.
PMID: 27012512
citation: Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;:
PMID: 31986264
citation: Ithete NL, Stoffberg S, Corman VM, Cottontail VM, Richards LR, Schoeman MC, Drosten C, Drexler JF, Preiser W. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis. 2013 Oct;19(10):1697-9. doi: 10.3201/eid1910.130946. No abstract available.
PMID: 24050621
citation: Sarris J, Kavanagh DJ. Kava and St. John's Wort: current evidence for use in mood and anxiety disorders. J Altern Complement Med. 2009 Aug;15(8):827-36. doi: 10.1089/acm.2009.0066.
PMID: 19614563
citation: Alagaili AN, Briese T, Mishra N, Kapoor V, Sameroff SC, Burbelo PD, de Wit E, Munster VJ, Hensley LE, Zalmout IS, Kapoor A, Epstein JH, Karesh WB, Daszak P, Mohammed OB, Lipkin WI. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio. 2014 Feb 25;5(2):e00884-14. doi: 10.1128/mBio.00884-14. Erratum In: MBio. 2014;5(2):e01002-14. Burbelo, Peter D [added].
PMID: 24570370
citation: Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, Butt KM, Wong KL, Chan KW, Lim W, Shortridge KF, Yuen KY, Peiris JS, Poon LL. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003 Oct 10;302(5643):276-8. doi: 10.1126/science.1087139. Epub 2003 Sep 4.
PMID: 12958366
citation: Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3. Erratum In: Nature. 2020 Dec;588(7836):E6.
PMID: 32015507
citation: Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottier PJ, Osterhaus AD, Bosch BJ, Haagmans BL. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013 Mar 14;495(7440):251-4. doi: 10.1038/nature12005.
PMID: 23486063
citation: Qian Z, Travanty EA, Oko L, Edeen K, Berglund A, Wang J, Ito Y, Holmes KV, Mason RJ. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. Am J Respir Cell Mol Biol. 2013 Jun;48(6):742-8. doi: 10.1165/rcmb.2012-0339OC.
PMID: 23418343
citation: Ji W, Li X. Response to comments on "Cross-species Transmission of the Newly Identified Coronavirus 2019-nCoV" and "Codon bias analysis may be insufficient for identifying host(s) of a novel virus". J Med Virol. 2020 Sep;92(9):1440. doi: 10.1002/jmv.26048. Epub 2020 Jul 14. No abstract available.
PMID: 32437080
citation: Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, Ippolito G, Mchugh TD, Memish ZA, Drosten C, Zumla A, Petersen E. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020 Feb;91:264-266. doi: 10.1016/j.ijid.2020.01.009. Epub 2020 Jan 14. No abstract available.
PMID: 31953166
citation: Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020 Apr;92(4):418-423. doi: 10.1002/jmv.25681. Epub 2020 Feb 7. Erratum In: J Med Virol. 2020 Oct;92(10):2249.
PMID: 31967327
citation: Khan S, Nabi G, Han G, Siddique R, Lian S, Shi H, Bashir N, Ali A, Shereen MA. Novel coronavirus: how things are in Wuhan. Clin Microbiol Infect. 2020 Apr;26(4):399-400. doi: 10.1016/j.cmi.2020.02.005. Epub 2020 Feb 11. No abstract available.
PMID: 32058086
citation: Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012 Nov 8;367(19):1814-20. doi: 10.1056/NEJMoa1211721. Epub 2012 Oct 17. Erratum In: N Engl J Med. 2013 Jul 25;369(4):394.
PMID: 23075143
citation: Bawazir A, Al-Mazroo E, Jradi H, Ahmed A, Badri M. MERS-CoV infection: Mind the public knowledge gap. J Infect Public Health. 2018 Jan-Feb;11(1):89-93. doi: 10.1016/j.jiph.2017.05.003. Epub 2017 Jun 21.
PMID: 28647126
citation: Zhong NS, Zheng BJ, Li YM, Poon, Xie ZH, Chan KH, Li PH, Tan SY, Chang Q, Xie JP, Liu XQ, Xu J, Li DX, Yuen KY, Peiris, Guan Y. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003 Oct 25;362(9393):1353-8. doi: 10.1016/s0140-6736(03)14630-2.
PMID: 14585636
citation: Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019 Mar;17(3):181-192. doi: 10.1038/s41579-018-0118-9.
PMID: 30531947
citation: Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020 Feb 29;395(10225):689-697. doi: 10.1016/S0140-6736(20)30260-9. Epub 2020 Jan 31. Erratum In: Lancet. 2020 Feb 4;:
PMID: 32014114
citation: Kim K, Andrew SA, Jung K. Public Health Network Structure and Collaboration Effectiveness during the 2015 MERS Outbreak in South Korea: An Institutional Collective Action Framework. Int J Environ Res Public Health. 2017 Sep 15;14(9):1064. doi: 10.3390/ijerph14091064.
PMID: 28914780
citation: Malave A, Elamin EM. Severe Acute Respiratory Syndrome (SARS)-Lessons for Future Pandemics. Virtual Mentor. 2010 Sep 1;12(9):719-25. doi: 10.1001/virtualmentor.2010.12.9.cprl1-1009. No abstract available.
PMID: 23186878
citation: Park JE, Jung S, Kim A, Park JE. MERS transmission and risk factors: a systematic review. BMC Public Health. 2018 May 2;18(1):574. doi: 10.1186/s12889-018-5484-8.
PMID: 29716568
citation: Al-Tawfiq JA, Auwaerter PG. Healthcare-associated infections: the hallmark of Middle East respiratory syndrome coronavirus with review of the literature. J Hosp Infect. 2019 Jan;101(1):20-29. doi: 10.1016/j.jhin.2018.05.021. Epub 2018 Jun 1.
PMID: 29864486
citation: Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. JAMA. 2020 Feb 25;323(8):707-708. doi: 10.1001/jama.2020.0757. No abstract available.
PMID: 31971553
citation: Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F, AlSaedi A, Mandourah Y, Almekhlafi GA, Sherbeeni NM, Elzein FE, Memon J, Taha Y, Almotairi A, Maghrabi KA, Qushmaq I, Al Bshabshe A, Kharaba A, Shalhoub S, Jose J, Fowler RA, Hayden FG, Hussein MA; And the MIRACLE trial group. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018 Jan 30;19(1):81. doi: 10.1186/s13063-017-2427-0.
PMID: 29382391
citation: Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4956-4961. doi: 10.26355/eurrev_201808_15635.
PMID: 30070331
citation: Kim KH, Tandi TE, Choi JW, Moon JM, Kim MS. Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: epidemiology, characteristics and public health implications. J Hosp Infect. 2017 Feb;95(2):207-213. doi: 10.1016/j.jhin.2016.10.008. Epub 2016 Oct 14.
PMID: 28153558
citation: Al-Omari A, Rabaan AA, Salih S, Al-Tawfiq JA, Memish ZA. MERS coronavirus outbreak: Implications for emerging viral infections. Diagn Microbiol Infect Dis. 2019 Mar;93(3):265-285. doi: 10.1016/j.diagmicrobio.2018.10.011. Epub 2018 Oct 18.
PMID: 30413355
citation: de Araujo Lopes A, da Fonseca FN, Rocha TM, de Freitas LB, Araujo EVO, Wong DVT, Lima Junior RCP, Leal LKAM. Eugenol as a Promising Molecule for the Treatment of Dermatitis: Antioxidant and Anti-inflammatory Activities and Its Nanoformulation. Oxid Med Cell Longev. 2018 Dec 11;2018:8194849. doi: 10.1155/2018/8194849. eCollection 2018.
PMID: 30647816
citation: Bachiega TF, de Sousa JP, Bastos JK, Sforcin JM. Clove and eugenol in noncytotoxic concentrations exert immunomodulatory/anti-inflammatory action on cytokine production by murine macrophages. J Pharm Pharmacol. 2012 Apr;64(4):610-6. doi: 10.1111/j.2042-7158.2011.01440.x. Epub 2012 Feb 7.
PMID: 22420667
citation: Kim SS, Oh OJ, Min HY, Park EJ, Kim Y, Park HJ, Nam Han Y, Lee SK. Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW264.7 cells. Life Sci. 2003 Jun 6;73(3):337-48. doi: 10.1016/s0024-3205(03)00288-1.
PMID: 12757841
citation: Yogalakshmi B, Viswanathan P, Anuradha CV. Investigation of antioxidant, anti-inflammatory and DNA-protective properties of eugenol in thioacetamide-induced liver injury in rats. Toxicology. 2010 Feb 9;268(3):204-12. doi: 10.1016/j.tox.2009.12.018. Epub 2009 Dec 29. Erratum In: Toxicology. 2021 May 30;456:152781.
PMID: 20036707
citation: Mnafgui K, Hajji R, Derbali F, Gammoudi A, Khabbabi G, Ellefi H, Allouche N, Kadri A, Gharsallah N. Anti-inflammatory, Antithrombotic and Cardiac Remodeling Preventive Effects of Eugenol in Isoproterenol-Induced Myocardial Infarction in Wistar Rat. Cardiovasc Toxicol. 2016 Oct;16(4):336-44. doi: 10.1007/s12012-015-9343-x.
PMID: 26391896
citation: Pan C, Dong Z. Antiasthmatic Effects of Eugenol in a Mouse Model of Allergic Asthma by Regulation of Vitamin D3 Upregulated Protein 1/NF-kappaB Pathway. Inflammation. 2015 Aug;38(4):1385-93. doi: 10.1007/s10753-015-0110-8.
PMID: 25588851
citation: Abuohashish HM, Khairy DA, Abdelsalam MM, Alsayyah A, Ahmed MM, Al-Rejaie SS. In-vivo assessment of the osteo-protective effects of eugenol in alveolar bone tissues. Biomed Pharmacother. 2018 Jan;97:1303-1310. doi: 10.1016/j.biopha.2017.11.068. Epub 2017 Dec 14.
PMID: 29156519
citation: Deepak V, Kasonga A, Kruger MC, Coetzee M. Inhibitory effects of eugenol on RANKL-induced osteoclast formation via attenuation of NF-kappaB and MAPK pathways. Connect Tissue Res. 2015 Jun;56(3):195-203. doi: 10.3109/03008207.2014.989320. Epub 2014 Dec 11.
PMID: 25405641
citation: Hussain T, Tan B, Yin Y, Blachier F, Tossou MC, Rahu N. Oxidative Stress and Inflammation: What Polyphenols Can Do for Us? Oxid Med Cell Longev. 2016;2016:7432797. doi: 10.1155/2016/7432797. Epub 2016 Sep 22.
PMID: 27738491
citation: Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010 Dec 1;49(11):1603-16. doi: 10.1016/j.freeradbiomed.2010.09.006. Epub 2010 Sep 16.
PMID: 20840865
citation: Ambade A, Mandrekar P. Oxidative stress and inflammation: essential partners in alcoholic liver disease. Int J Hepatol. 2012;2012:853175. doi: 10.1155/2012/853175. Epub 2012 Mar 1.
PMID: 22500241
citation: Garcia N, Zazueta C, Aguilera-Aguirre L. Oxidative Stress and Inflammation in Cardiovascular Disease. Oxid Med Cell Longev. 2017;2017:5853238. doi: 10.1155/2017/5853238. Epub 2017 Apr 27. No abstract available.
PMID: 28536646
citation: Capasso A. Antioxidant action and therapeutic efficacy of Allium sativum L. Molecules. 2013 Jan 4;18(1):690-700. doi: 10.3390/molecules18010690.
PMID: 23292331
citation: Gu X, Wu H, Fu P. Allicin attenuates inflammation and suppresses HLA-B27 protein expression in ankylosing spondylitis mice. Biomed Res Int. 2013;2013:171573. doi: 10.1155/2013/171573. Epub 2013 Nov 13.
PMID: 24324956
citation: Ban JO, Yuk DY, Woo KS, Kim TM, Lee US, Jeong HS, Kim DJ, Chung YB, Hwang BY, Oh KW, Hong JT. Inhibition of cell growth and induction of apoptosis via inactivation of NF-kappaB by a sulfurcompound isolated from garlic in human colon cancer cells. J Pharmacol Sci. 2007 Aug;104(4):374-83. doi: 10.1254/jphs.fp0070789.
PMID: 17721042
citation: Macpherson LJ, Geierstanger BH, Viswanath V, Bandell M, Eid SR, Hwang S, Patapoutian A. The pungency of garlic: activation of TRPA1 and TRPV1 in response to allicin. Curr Biol. 2005 May 24;15(10):929-34. doi: 10.1016/j.cub.2005.04.018.
PMID: 15916949
citation: Alpers DH. Garlic and its potential for prevention of colorectal cancer and other conditions. Curr Opin Gastroenterol. 2009 Mar;25(2):116-21. doi: 10.1097/MOG.0b013e32831ef221. No abstract available.
PMID: 19528879
citation: Shen Y, Jia LN, Honma N, Hosono T, Ariga T, Seki T. Beneficial effects of cinnamon on the metabolic syndrome, inflammation, and pain, and mechanisms underlying these effects - a review. J Tradit Complement Med. 2012 Jan;2(1):27-32. doi: 10.1016/s2225-4110(16)30067-0.
PMID: 24716111
citation: Ta CA, Arnason JT. Mini Review of Phytochemicals and Plant Taxa with Activity as Microbial Biofilm and Quorum Sensing Inhibitors. Molecules. 2015 Dec 26;21(1):E29. doi: 10.3390/molecules21010029.
PMID: 26712734
citation: Anand David AV, Arulmoli R, Parasuraman S. Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid. Pharmacogn Rev. 2016 Jul-Dec;10(20):84-89. doi: 10.4103/0973-7847.194044.
PMID: 28082789
citation: Senchina DS, Hallam JE, Dias AS, Perera MA. Human blood mononuclear cell in vitro cytokine response before and after two different strenuous exercise bouts in the presence of bloodroot and Echinacea extracts. Blood Cells Mol Dis. 2009 Nov-Dec;43(3):298-303. doi: 10.1016/j.bcmd.2009.08.003. Epub 2009 Sep 19.
PMID: 19766513
citation: Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol. 1997 Jul;19(7):371-9. doi: 10.1016/s0192-0561(97)00061-1.
PMID: 9568541
citation: Ma XL, Meng M, Han LR, Li Z, Cao XH, Wang CL. Immunomodulatory activity of macromolecular polysaccharide isolated from Grifola frondosa. Chin J Nat Med. 2015 Dec;13(12):906-14. doi: 10.1016/S1875-5364(15)30096-0.
PMID: 26721709
citation: Tulk SE, Liao KC, Muruve DA, Li Y, Beck PL, MacDonald JA. Vitamin D(3) metabolites enhance the NLRP3-dependent secretion of IL-1beta from human THP-1 monocytic cells. J Cell Biochem. 2015 May;116(5):711-20. doi: 10.1002/jcb.24985.
PMID: 25639477
citation: Verway M, Bouttier M, Wang TT, Carrier M, Calderon M, An BS, Devemy E, McIntosh F, Divangahi M, Behr MA, White JH. Vitamin D induces interleukin-1beta expression: paracrine macrophage epithelial signaling controls M. tuberculosis infection. PLoS Pathog. 2013;9(6):e1003407. doi: 10.1371/journal.ppat.1003407. Epub 2013 Jun 6.
PMID: 23762029
citation: Rao Z, Chen X, Wu J, Xiao M, Zhang J, Wang B, Fang L, Zhang H, Wang X, Yang S, Chen Y. Vitamin D Receptor Inhibits NLRP3 Activation by Impeding Its BRCC3-Mediated Deubiquitination. Front Immunol. 2019 Dec 4;10:2783. doi: 10.3389/fimmu.2019.02783. eCollection 2019.
PMID: 31866999
citation: Lu L, Lu Q, Chen W, Li J, Li C, Zheng Z. Vitamin D3 Protects against Diabetic Retinopathy by Inhibiting High-Glucose-Induced Activation of the ROS/TXNIP/NLRP3 Inflammasome Pathway. J Diabetes Res. 2018 Feb 22;2018:8193523. doi: 10.1155/2018/8193523. eCollection 2018.
PMID: 29682582
citation: Ulbricht C, Basch E, Cheung L, Goldberg H, Hammerness P, Isaac R, Khalsa KP, Romm A, Rychlik I, Varghese M, Weissner W, Windsor RC, Wortley J. An evidence-based systematic review of elderberry and elderflower (Sambucus nigra) by the Natural Standard Research Collaboration. J Diet Suppl. 2014 Mar;11(1):80-120. doi: 10.3109/19390211.2013.859852. Epub 2014 Jan 10.
PMID: 24409980
citation: Chen C, Zuckerman DM, Brantley S, Sharpe M, Childress K, Hoiczyk E, Pendleton AR. Sambucus nigra extracts inhibit infectious bronchitis virus at an early point during replication. BMC Vet Res. 2014 Jan 16;10:24. doi: 10.1186/1746-6148-10-24.
PMID: 24433341
citation: Weng JR, Lin CS, Lai HC, Lin YP, Wang CY, Tsai YC, Wu KC, Huang SH, Lin CW. Antiviral activity of Sambucus FormosanaNakai ethanol extract and related phenolic acid constituents against human coronavirus NL63. Virus Res. 2019 Nov;273:197767. doi: 10.1016/j.virusres.2019.197767. Epub 2019 Sep 24.
PMID: 31560964
citation: Hemila H. Vitamin C supplementation and respiratory infections: a systematic review. Mil Med. 2004 Nov;169(11):920-5. doi: 10.7205/milmed.169.11.920.
PMID: 15605943
citation: Choe JY, Kim SK. Quercetin and Ascorbic Acid Suppress Fructose-Induced NLRP3 Inflammasome Activation by Blocking Intracellular Shuttling of TXNIP in Human Macrophage Cell Lines. Inflammation. 2017 Jun;40(3):980-994. doi: 10.1007/s10753-017-0542-4.
PMID: 28326454
citation: Dabbagh-Bazarbachi H, Clergeaud G, Quesada IM, Ortiz M, O'Sullivan CK, Fernandez-Larrea JB. Zinc ionophore activity of quercetin and epigallocatechin-gallate: from Hepa 1-6 cells to a liposome model. J Agric Food Chem. 2014 Aug 13;62(32):8085-93. doi: 10.1021/jf5014633. Epub 2014 Jul 31.
PMID: 25050823
citation: Kaihatsu K, Yamabe M, Ebara Y. Antiviral Mechanism of Action of Epigallocatechin-3-O-gallate and Its Fatty Acid Esters. Molecules. 2018 Sep 27;23(10):2475. doi: 10.3390/molecules23102475.
PMID: 30262731
citation: Wen CC, Kuo YH, Jan JT, Liang PH, Wang SY, Liu HG, Lee CK, Chang ST, Kuo CJ, Lee SS, Hou CC, Hsiao PW, Chien SC, Shyur LF, Yang NS. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007 Aug 23;50(17):4087-95. doi: 10.1021/jm070295s. Epub 2007 Jul 31.
PMID: 17663539
citation: Chen H, Lin H, Xie S, Huang B, Qian Y, Chen K, Niu Y, Shen HM, Cai J, Li P, Leng J, Yang H, Xia D, Wu Y. Myricetin inhibits NLRP3 inflammasome activation via reduction of ROS-dependent ubiquitination of ASC and promotion of ROS-independent NLRP3 ubiquitination. Toxicol Appl Pharmacol. 2019 Feb 15;365:19-29. doi: 10.1016/j.taap.2018.12.019. Epub 2018 Dec 27.
PMID: 30594691
citation: Yamagata K, Hashiguchi K, Yamamoto H, Tagami M. Dietary Apigenin Reduces Induction of LOX-1 and NLRP3 Expression, Leukocyte Adhesion, and Acetylated Low-Density Lipoprotein Uptake in Human Endothelial Cells Exposed to Trimethylamine-N-Oxide. J Cardiovasc Pharmacol. 2019 Dec;74(6):558-565. doi: 10.1097/FJC.0000000000000747.
PMID: 31815868
citation: Lim H, Min DS, Park H, Kim HP. Flavonoids interfere with NLRP3 inflammasome activation. Toxicol Appl Pharmacol. 2018 Sep 15;355:93-102. doi: 10.1016/j.taap.2018.06.022. Epub 2018 Jun 28.
PMID: 29960001
citation: Phillips JM, Gallagher T, Weiss SR. Neurovirulent Murine Coronavirus JHM.SD Uses Cellular Zinc Metalloproteases for Virus Entry and Cell-Cell Fusion. J Virol. 2017 Mar 29;91(8):e01564-16. doi: 10.1128/JVI.01564-16. Print 2017 Apr 15.
PMID: 28148786
citation: Romero JM, Grunwald B, Jang GH, Bavi PP, Jhaveri A, Masoomian M, Fischer SE, Zhang A, Denroche RE, Lungu IM, De Luca A, Bartlett JMS, Xu J, Li N, Dhaliwal S, Liang SB, Chadwick D, Vyas F, Bronsert P, Khokha R, McGaha TL, Notta F, Ohashi PS, Done SJ, O'Kane GM, Wilson JM, Knox JJ, Connor A, Wang Y, Zogopoulos G, Gallinger S. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. Clin Cancer Res. 2020 Apr 15;26(8):1997-2010. doi: 10.1158/1078-0432.CCR-19-2803. Epub 2020 Jan 21.
PMID: 31964786
citation: Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, Farber JM, Fairchild RL. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol. 2007 Feb 15;178(4):2278-86. doi: 10.4049/jimmunol.178.4.2278.
PMID: 17277133
citation: Prather AA, Janicki-Deverts D, Hall MH, Cohen S. Behaviorally Assessed Sleep and Susceptibility to the Common Cold. Sleep. 2015 Sep 1;38(9):1353-9. doi: 10.5665/sleep.4968.
PMID: 26118561
citation: Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.
PMID: 32132184
citation: Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q, Wu J. Coronavirus infections and immune responses. J Med Virol. 2020 Apr;92(4):424-432. doi: 10.1002/jmv.25685. Epub 2020 Feb 7.
PMID: 31981224
citation: He Y, Hara H, Nunez G. Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem Sci. 2016 Dec;41(12):1012-1021. doi: 10.1016/j.tibs.2016.09.002. Epub 2016 Sep 23.
PMID: 27669650
citation: Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16. No abstract available.
PMID: 32192578
citation: Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. No abstract available. Erratum In: Lancet Respir Med. 2020 Feb 25;:
PMID: 32085846
citation: Sutterwala FS, Haasken S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 2014 Jun;1319(1):82-95. doi: 10.1111/nyas.12458. Epub 2014 May 19.
PMID: 24840700
citation: Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30. No abstract available.
PMID: 32227760
citation: Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 2005 Feb;45(2):163-9. doi: 10.1161/01.HYP.0000153321.13792.b9. Epub 2005 Jan 3.
PMID: 15630047
citation: Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F, Romero JP, Wirnsberger G, Zhang H, Slutsky AS, Conder R, Montserrat N, Mirazimi A, Penninger JM. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020 May 14;181(4):905-913.e7. doi: 10.1016/j.cell.2020.04.004. Epub 2020 Apr 24.
PMID: 32333836
citation: Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, Smoot J, Gregg AC, Daniels AD, Jervey S, Albaiu D. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci. 2020 Mar 25;6(3):315-331. doi: 10.1021/acscentsci.0c00272. Epub 2020 Mar 12. No abstract available.
PMID: 32226821
citation: Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 Apr 11;395(10231):1225-1228. doi: 10.1016/S0140-6736(20)30627-9. Epub 2020 Mar 13.
PMID: 32178769
citation: Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.
PMID: 32031570
citation: Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020 Mar 27;12(4):372. doi: 10.3390/v12040372.
PMID: 32230900
citation: Schindewolf C, Menachery VD. Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism. Viruses. 2019 Jan 17;11(1):74. doi: 10.3390/v11010074.
PMID: 30658390
responsible party type: Principal Investigator
investigator affiliation: Unidad de Investigación Genética Molecular
investigator full name: Beatriz Aristizabal
investigator title: Beatriz H Aristizabal B, MsC immunology, MsC Medical Genetics, PhD Molecular Biolgy, Scientific director of Unidad de Investigación Genética Molecular
mesh term: Infections
mesh term: Adjuvants, Immunologic
sharing ipd: No